KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Divestments (2025)

Recursion Pharmaceuticals' Divestments history spans 1 years, with the latest figure at -$4.4 million for Q1 2025.

  • For Q1 2025, Divestments changed N/A year-over-year to -$4.4 million; the TTM value through Dec 2025 reached -$4.4 million, changed N/A, while the annual FY2025 figure was -$4.4 million, N/A changed from the prior year.
  • Divestments reached -$4.4 million in Q1 2025 per RXRX's latest filing.
  • In the past five years, Divestments ranged from a high of -$4.4 million in Q1 2025 to a low of -$4.4 million in Q1 2025.